ETHAMBUTOL PLUS ISONIAZID COMPARED WITH RIFAMPICIN PLUS ISONIAZID IN ANTITUBERCULOSIS CONTINUATION TREATMENT
Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1977-06, Vol.309 (8024), p.1232-1233 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1233 |
|---|---|
| container_issue | 8024 |
| container_start_page | 1232 |
| container_title | The Lancet (British edition) |
| container_volume | 309 |
| creator | Lees, A.W. Smith, J. Allan, G.W. Tyrrell, W.F. |
| description | Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus isoniazid (E+I). 63 patients in each continuation group were followed up for at least one year, and no relapses occurred. Continuation treatment with E+I was as effective and acceptable as that with R+I and was much less costly. |
| doi_str_mv | 10.1016/S0140-6736(77)92439-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2156452224</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673677924394</els_id><sourcerecordid>2156452224</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-d60fa0eeaac9716034ad96f9904272b95589af132e20a89d677555fb653b4b843</originalsourceid><addsrcrecordid>eNqFkMtKw0AUhgdRsFYfQQi40UV0ZjKXzkpimtqBXEoyQXEz5DKBlNrWpBV8e5NWXLhxdeDw_f_hfABcI3iPIGIPKUQE2ow77JbzO4GJI2xyAkaIcGJTwl9PwegXOQcXXbeEEBIG6QisfDV3w6dMxYG1CLLUkmkcSfdNTi0vDhdu4k-tF6nmViJnbriQnoz-cv3GjZRU2ZOfeFkQpzLts_0mylwl48hSie-q0I_UJTir81Vnrn7mGGQzX3lzO4ifpecGdokp3NkVg3UOjcnzUnDEoEPySrBaCEgwx4WgdCLyGjnYYJhPRMU4p5TWBaNOQYoJccbg5ti7bTcfe9Pt9HKzb9f9SY0RZYRijAeKHqmy3XRda2q9bZv3vP3SCOpBrD6I1YM1zbk-iNVD7vGYM_0Ln41pdVc2Zl2aqmlNudPVpvmn4RspKXZp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2156452224</pqid></control><display><type>article</type><title>ETHAMBUTOL PLUS ISONIAZID COMPARED WITH RIFAMPICIN PLUS ISONIAZID IN ANTITUBERCULOSIS CONTINUATION TREATMENT</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lees, A.W. ; Smith, J. ; Allan, G.W. ; Tyrrell, W.F.</creator><creatorcontrib>Lees, A.W. ; Smith, J. ; Allan, G.W. ; Tyrrell, W.F.</creatorcontrib><description>Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus isoniazid (E+I). 63 patients in each continuation group were followed up for at least one year, and no relapses occurred. Continuation treatment with E+I was as effective and acceptable as that with R+I and was much less costly.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(77)92439-4</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Ethambutol ; Isoniazid ; Patients ; Rifampin ; Tuberculosis</subject><ispartof>The Lancet (British edition), 1977-06, Vol.309 (8024), p.1232-1233</ispartof><rights>1977</rights><rights>Copyright Elsevier Limited Jun 11, 1977</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c250t-d60fa0eeaac9716034ad96f9904272b95589af132e20a89d677555fb653b4b843</citedby><cites>FETCH-LOGICAL-c250t-d60fa0eeaac9716034ad96f9904272b95589af132e20a89d677555fb653b4b843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0140-6736(77)92439-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Lees, A.W.</creatorcontrib><creatorcontrib>Smith, J.</creatorcontrib><creatorcontrib>Allan, G.W.</creatorcontrib><creatorcontrib>Tyrrell, W.F.</creatorcontrib><title>ETHAMBUTOL PLUS ISONIAZID COMPARED WITH RIFAMPICIN PLUS ISONIAZID IN ANTITUBERCULOSIS CONTINUATION TREATMENT</title><title>The Lancet (British edition)</title><description>Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus isoniazid (E+I). 63 patients in each continuation group were followed up for at least one year, and no relapses occurred. Continuation treatment with E+I was as effective and acceptable as that with R+I and was much less costly.</description><subject>Ethambutol</subject><subject>Isoniazid</subject><subject>Patients</subject><subject>Rifampin</subject><subject>Tuberculosis</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1977</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKw0AUhgdRsFYfQQi40UV0ZjKXzkpimtqBXEoyQXEz5DKBlNrWpBV8e5NWXLhxdeDw_f_hfABcI3iPIGIPKUQE2ow77JbzO4GJI2xyAkaIcGJTwl9PwegXOQcXXbeEEBIG6QisfDV3w6dMxYG1CLLUkmkcSfdNTi0vDhdu4k-tF6nmViJnbriQnoz-cv3GjZRU2ZOfeFkQpzLts_0mylwl48hSie-q0I_UJTir81Vnrn7mGGQzX3lzO4ifpecGdokp3NkVg3UOjcnzUnDEoEPySrBaCEgwx4WgdCLyGjnYYJhPRMU4p5TWBaNOQYoJccbg5ti7bTcfe9Pt9HKzb9f9SY0RZYRijAeKHqmy3XRda2q9bZv3vP3SCOpBrD6I1YM1zbk-iNVD7vGYM_0Ln41pdVc2Zl2aqmlNudPVpvmn4RspKXZp</recordid><startdate>19770611</startdate><enddate>19770611</enddate><creator>Lees, A.W.</creator><creator>Smith, J.</creator><creator>Allan, G.W.</creator><creator>Tyrrell, W.F.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>ASE</scope><scope>C1K</scope><scope>FPQ</scope><scope>H94</scope><scope>K6X</scope><scope>K9.</scope><scope>KB~</scope><scope>M7N</scope><scope>NAPCQ</scope></search><sort><creationdate>19770611</creationdate><title>ETHAMBUTOL PLUS ISONIAZID COMPARED WITH RIFAMPICIN PLUS ISONIAZID IN ANTITUBERCULOSIS CONTINUATION TREATMENT</title><author>Lees, A.W. ; Smith, J. ; Allan, G.W. ; Tyrrell, W.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-d60fa0eeaac9716034ad96f9904272b95589af132e20a89d677555fb653b4b843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1977</creationdate><topic>Ethambutol</topic><topic>Isoniazid</topic><topic>Patients</topic><topic>Rifampin</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lees, A.W.</creatorcontrib><creatorcontrib>Smith, J.</creatorcontrib><creatorcontrib>Allan, G.W.</creatorcontrib><creatorcontrib>Tyrrell, W.F.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>British Nursing Index</collection><collection>Environmental Sciences and Pollution Management</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Newsstand Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lees, A.W.</au><au>Smith, J.</au><au>Allan, G.W.</au><au>Tyrrell, W.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ETHAMBUTOL PLUS ISONIAZID COMPARED WITH RIFAMPICIN PLUS ISONIAZID IN ANTITUBERCULOSIS CONTINUATION TREATMENT</atitle><jtitle>The Lancet (British edition)</jtitle><date>1977-06-11</date><risdate>1977</risdate><volume>309</volume><issue>8024</issue><spage>1232</spage><epage>1233</epage><pages>1232-1233</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>Patients with bacteriologically positive pulmonary tuberculosis were treated initially for an average of three and a half months with isoniazid, rifampicin, and ethambutol and then a total of one year's treatment was completed with either rifampicin plus isoniazid (R+I) or with ethambutol plus isoniazid (E+I). 63 patients in each continuation group were followed up for at least one year, and no relapses occurred. Continuation treatment with E+I was as effective and acceptable as that with R+I and was much less costly.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S0140-6736(77)92439-4</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1977-06, Vol.309 (8024), p.1232-1233 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2156452224 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Ethambutol Isoniazid Patients Rifampin Tuberculosis |
| title | ETHAMBUTOL PLUS ISONIAZID COMPARED WITH RIFAMPICIN PLUS ISONIAZID IN ANTITUBERCULOSIS CONTINUATION TREATMENT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A06%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ETHAMBUTOL%20PLUS%20ISONIAZID%20COMPARED%20WITH%20RIFAMPICIN%20PLUS%20ISONIAZID%20IN%20ANTITUBERCULOSIS%20CONTINUATION%20TREATMENT&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Lees,%20A.W.&rft.date=1977-06-11&rft.volume=309&rft.issue=8024&rft.spage=1232&rft.epage=1233&rft.pages=1232-1233&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(77)92439-4&rft_dat=%3Cproquest_cross%3E2156452224%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2156452224&rft_id=info:pmid/&rft_els_id=S0140673677924394&rfr_iscdi=true |